In the dynamic field of hematology and oncology, innovative treatments for systemic amyloid light chain (AL) amyloidosis are essential. Recent research, led by Professor Yangqiu Li from the Institute of Hematology, School of Medicine, Jinan University,, explores immune checkpoint expression patterns in AL amyloidosis. This study investigates VISTA+, PD-1+, Tim-3+, and TIGIT+ T cells in newly diagnosed patients, highlighting the immunosuppressive environment of the disease.The findings reveal the potential of targeting VISTA, PD-1, and TIGIT to reverse T-cell exhaustion, offering new therapeutic avenues.

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from all over the world each year to share and discuss innovative ideas and the latest scientific and clinical research results in hematology. At this year's EHA conference, two studies by Professor Li Wang's team from Ruijin Hospital, Shanghai JiaoTong University School of Medicine (abstracts P1716 and 2074), explored minimal residual disease (MRD) monitoring in diffuse large B-cell lymphoma (DLBCL) and the application of the new BTK inhibitor orelabrutinib in the treatment of indolent non-Hodgkin lymphoma (iNHL). Oncology Frontier - Hematology Frontier specially translated and organized the content of these two studies for readers' reference.

From June 22 to June 26, 2024, the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) Congress was held in Bangkok, Thailand. As the most influential international event in the field of thrombosis and hemostasis, the ISTH Congress attracts thousands of top experts and scholars from around the world with its profound academic impact and rich content. At this grand event, "Oncology Frontier - Hematology Frontier" had the honor of interviewing Academician Heyu Ni of the Canadian Academy of Health Sciences, who also serves as the chairman of the Joint ISTH Conference of Global Chinese Thrombosis and Hemostasis. In the interview, Academician Ni shared his extensive academic background and unique insights, offering us valuable academic reflections and insights. Here is the interview in text form for our readers.

Chronic myeloid leukemia (CML) requires long-term treatment, emphasizing the importance of both efficacy and long-term safety and tolerability to achieve treatment goals, including treatment-free remission (TFR). Asciminib (ASC) is the first specific inhibitor targeting the ABL myristoyl pocket (STAMP) of BCR:ABL1, offering high specificity and minimal off-target effects. From June 13-16, 2024, the 29th Annual Meeting of the European Hematology Association (EHA) was held in Madrid, Spain. At the conference, an international multicenter phase III randomized controlled study, ASC4FIRST (NCT04971226), compared the efficacy and safety of ASC with standard first-line TKIs for newly diagnosed CML patients. The results demonstrated that ASC as a first-line treatment for newly diagnosed CML has superior efficacy, safety, and tolerability compared to current TKIs. We have invited Professor Bingcheng Liu from the Leukemia Treatment Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , to review this study.

Lymphoma, a common malignant tumor of the hematological system, has always been a focus of research for innovative and optimized treatment strategies. In recent years, with the rise of immunotherapy and targeted therapy, lymphoma treatment strategies are undergoing revolutionary changes. The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June 13-16, 2024, in Madrid, Spain. With the rapid development of hematology, Chinese research teams also showcased many innovative treatment plans and clinical research results at this year's EHA conference. At this meeting, Professor Haiwen Huang from The First Affiliated Hospital of Soochow University announced the results of a study on zanubrutinib combined with rituximab and chemotherapy (ZR-chemo) for the treatment of newly diagnosed mantle cell lymphoma. "Oncology Frontier - Hematology Frontier" invited Professor Haiwen Huang to share and interpret the findings of this study.